Bhardwaj, Nina

Immunology of COVID-19: Current State of the Science

Vabret, N., Britton, G. J., Gruber, C., Hegde, S., Kim, J., Kuksin, M., Levantovsky, R., Malle, L., Moreira, A., Park, M. D., et al. (2020) · Immunity

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 1,623

Therapeutic cancer vaccines

Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021) · Nature reviews. Cancer

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 1,581

Immature Dendritic Cells Phagocytose Apoptotic Cells via αvβ5 and CD36, and Cross-present Antigens to Cytotoxic T Lymphocytes

Albert, M. L., Pearce, S. F. A., Francisco, L. M., Sauter, B., Roy, P., Silverstein, R. L., & Bhardwaj, N. (1998) · The Journal of Experimental Medicine

Immunotherapy and Immune ResponsesPhagocytosis and Immune Regulation

Cited by 1,234

A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments

Barry, K. C., Hsu, J., Broz, M. L., Cueto, F. J., Binnewies, M., Combes, A. J., Nelson, A. E., Loo, K., Kumar, R., Rosenblum, M. D., et al. (2018) · Nature Medicine

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 1,021

A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer

Ott, P. A., Hu-Lieskovan, S., Chmielowski, B., Govindan, R., Naing, A., Bhardwaj, N., Margolin, K., Awad, M. M., Hellmann, M. D., Lin, J. J., et al. (2020) · Cell

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 738

Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction

Wells, D. K., van Buuren, M. M., Dang, K. K., Hubbard-Lucey, V. M., Sheehan, K. C. F., Campbell, K. M., Lamb, A., Ward, J. P., Sidney, J., Blazquez, A. B., et al. (2020) · Cell

vaccines and immunoinformatics approachesCancer Immunotherapy and Biomarkers

Cited by 538

EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer

Wang, L., Saci, A., Szabo, P. M., Chasalow, S. D., Castillo-Martin, M., Domingo-Domenech, J., Siefker-Radtke, A., Sharma, P., Sfakianos, J. P., Gong, Y., et al. (2018) · Nature Communications

Cancer Immunotherapy and BiomarkersBladder and Urothelial Cancer Treatments

Cited by 313

TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer

Park, M. D., Reyes-Torres, I., LeBerichel, J., Hamon, P., LaMarche, N. M., Hegde, S., Belabed, M., Troncoso, L., Grout, J. A., Magen, A., et al. (2023) · Nature Immunology

Immune cells in cancerImmune Cell Function and Interaction

Cited by 251

Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial

Marron, T. U., Fiel, M. I., Hamon, P., Fiaschi, N., Kim, E., Ward, S. C., Zhao, Z., Kim, J., Kennedy, P., Gunasekaran, G., et al. (2022) · The Lancet Gastroenterology & Hepatology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 239

Correlation between gene expression profiles and protein-protein interactions within and across genomes

Bhardwaj, N., & Lu, H. (2005) · Bioinformatics

Bioinformatics and Genomic NetworksGenomics and Phylogenetic Studies

Cited by 186

Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs

Weingarten-Gabbay, S., Klaeger, S., Sarkizova, S., Pearlman, L. R., Chen, D.-Y., Gallagher, K. M. E., Bauer, M. R., Taylor, H. B., Dunn, W. A., Tarr, C., et al. (2021) · Cell

vaccines and immunoinformatics approachesSARS-CoV-2 and COVID-19 Research

Cited by 147

Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing

Wang, L., Sfakianos, J. P., Beaumont, K. G., Akturk, G., Horowitz, A., Sebra, R. P., Farkas, A. M., Gnjatic, S., Hake, A., Izadmehr, S., et al. (2021) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersImmune cells in cancer

Cited by 97

Distinguishing the immunostimulatory properties of noncoding RNAs expressed in cancer cells

Tanne, A., Muniz, L. R., Puzio-Kuter, A., Leonova, K. I., Gudkov, A. V., Ting, D. T., Monasson, R., Cocco, S., Levine, A. J., Bhardwaj, N., et al. (2015) · Proceedings of the National Academy of Sciences

Immune Response and InflammationCancer-related molecular mechanisms research

Cited by 74

Sequence-Specific Sensing of Nucleic Acids

Vabret, N., Bhardwaj, N., & Greenbaum, B. D. (2017) · Trends in Immunology

Immune Response and Inflammationinterferon and immune responses

Cited by 45

Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery

Marron, T. U., Galsky, M. D., Taouli, B., Fiel, M. I., Ward, S., Kim, E., Yankelevitz, D., Doroshow, D., Guttman-Yassky, E., Ungar, B., et al. (2022) · Nature Medicine

Breast Cancer Treatment StudiesStatistical Methods in Clinical Trials

Cited by 30

PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting

Saxena, M., Marron, T. U., Kodysh, J., Finnigan, J. P., Onkar, S., Kaminska, A., Tuballes, K., Guo, R., Sabado, R. L., Meseck, M., et al. (2025) · Cancer Discovery

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 28